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Abstract
Background: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays critical
functions in many biological processes, including DNA repair and gene transcription. The main
function of PARP-1 is to catalyze the transfer of ADP-ribose units from nicotinamide adenine
dinucleotide (NAD+) to a large array of acceptor proteins, which comprises histones, transcription
factors, as well as PARP-1 itself. We have previously demonstrated that transcription of the PARP-
1 gene essentially rely on the opposite regulatory actions of two distinct transcription factors, Sp1
and NFI. In the present study, we examined whether suppression of PARP-1 expression in
embryonic fibroblasts derived from PARP-1 knockout mice (PARP-1-/-) might alter the expression
and/or DNA binding properties of Sp1 and NFI. We also explored the possibility that Sp1 or NFI
(or both) may represent target proteins of PARP-1 activity.
Results: Expression of both Sp1 and NFI was found to be considerably reduced in PARP-1-/- cells.
Co-immunoprecipitation assays revealed that PARP-1 physically interacts with Sp1 in a DNA-
independent manner, but neither with Sp3 nor NFI, in PARP-1+/+ cells. In addition, in vitro PARP
assays indicated that PARP-1 could catalyze the addition of polymer of ADP-ribose to Sp1, which
also translated into a reduction of Sp1 binding to its consensus DNA target site. Transfection of
the PARP-1 promoter into both PARP-1+/+ and PARP-1-/- cells revealed that the lack of PARP-1
expression in PARP-1-/- cells also results in a strong increase in PARP-1 promoter activity. This
influence of PARP-1 was found to rely on the presence of the Sp1 sites present on the basal PARP-
1 promoter as their mutation entirely abolished the increased promoter activity observed in PARP-
1-/- cells. Subjecting PARP-1+/+ cells to an oxidative challenge with hydrogen peroxide to increase
PARP-1 activity translated into a dramatic reduction in the DNA binding properties of Sp1.
However, its suppression by the inhibitor PJ34 improved DNA binding of Sp1 and led to a dramatic
increase in PARP-1 promoter function.
Conclusion: Our results therefore recognized Sp1 as a target protein of PARP-1 activity, the
addition of polymer of ADP-ribose to this transcription factor restricting its positive regulatory
influence on gene transcription.
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Background
Poly(ADP-ribose) polymerase-1 (PARP-1) is a highly evo-
lutionary preserved, multifunctional nuclear enzyme that
catalyzes the addition of ADP-ribose (ADPr) units from
nicotinamide adenine dinucleotide (NAD+) on a large
variety of nuclear proteins and consequently impinges on
many of the major nuclear functions (reviewed in [1]).
Gene inactivation studies have revealed and/or confirmed
up to nine biological functions for PARP-1 [2]. These
include both DNA repair and maintenance of genomic
integrity as well as regulation of telomerase activity [3,4]
(also reviewed in [5]). PARP-1 also regulates the expres-
sion of various proteins at the transcriptional level
(reviewed in [2]) and is also involved in DNA replication
as well as cell differentiation [6-8]. In addition, polymer
of ADP ribose (PAR) has been recently identified as an
emergency source of energy used by the base-excision
machinery to synthesize ATP [9,10]. PAR may also serve as
a signal to induce cell death [11]. Finally, PARP-1 may
contribute to the regulation of cytoskeletal organization
and in the post-transcriptional modification of nuclear
proteins like histones and transcription factors (reviewed
in [2,12]).
PARP-1 plays vital functions in gene transcription as it can
influence the state of chromatin remodeling through the
catalytic addition of PAR to the core histones [13,14].
Besides, PARP-1, through its double Zn-finger DNA bind-
ing domain, can interact with target regulatory elements
present in the promoter of many genes, including the
MCAT 1 [15], Pax-6 [16], MHC II [17], and the CXCL1
[18] genes. By exploiting both chromatin cross-linking
and immunoprecipitation assays, Soldatenkov and cow-
orkers elegantly demonstrated that PARP-1 could also
bind to secondary hairpin-like structures present in the 5'-
flanking region of the human PARP-1 promoter [19].
Although no prototypical sequence that could be recog-
nized as a target by the PARP-1 DBD has been identified
yet, Pion and collaborators have however demonstrated
the ability of the protein to bind to both 5'- and 3'-
recessed ends on double-stranded DNA, as well as to pal-
indromic-like structures often present in DNA [20]. Lastly,
PARP-1 can also alter gene transcription through its ability
to poly(ADP-ribosyl)ate several transcription factors, such
as YY1 [21], NFKB [22], TFIIF [23], Oct-1 [24], B-MYB [25]
and AP-2 [26], thereby preventing their binding with their
specific promoter target sites [27].
The studies conducted over the last few decades have been
mostly dedicated to the study of the many biological and
cellular functions of PARP-1. Unfortunately, not so many
studies have explored the molecular mechanisms that reg-
ulate the transcription of PARP-1 gene expression. Unlike
its enzymatic activity, PARP-1 gene transcription is not
activated by DNA strand breaks [28,29]. On the other
hand, PARP-1 gene expression appears related to cell pro-
liferation rather than DNA synthesis as PARP-1 mRNA has
been shown to be more abundant in the G1 phase of the
cell cycle [30-32]. To date, the PARP-1 promoter has been
cloned from three different mammalian species: human
[33], rat [34] and mouse [35]. All three mammalian basal
promoters share structural similarities typical of house-
keeping genes in that they lack a functional consensus
TATA box, possess a high content of GC-residues, and bear
a consensus initiator sequence (Inr) that overlaps the tran-
scription initiation site. The human promoter has been
shown to contain binding sites for the transcription fac-
tors Sp1, AP-2 [33], YY1 [21], and Ets [36], whereas the
mouse promoter was recently shown to be down-regu-
lated by a complex of adenovirus E1A protein and pRb
[35]. Studies that we conducted on the rat PARP-1
(rPARP-1) proximal promoter have shown that its activity
is primarily, but not entirely dependent on the recogni-
tion of five GC-rich binding sites (F1, F2, F3, F4 and US-
1) by the positive transcription factors Sp1 and Sp3
[37,38]. Other transcription factors, such as those that
belong to the Nuclear Factor I (NFI) family of transcrip-
tion factors [39], were also found to bind to nearby target
sites to alter the activity directed by the PARP-1 gene pro-
moter [39-41]. Sp1 and Sp3, two members from a Zn-fin-
ger family of transcription factors that presently comprises
nine proteins (Sp1 to Sp9) [42], often compete with each
other for the recognition of their common GC-rich target
sites [43,44]. However, Sp1 is a transcriptional activator,
while Sp3 can, according to the context, function either as
a repressor or an activator of gene transcription [43,45].
The NFI family is composed of four members encoded by
distinct genes, NFI-A, -B, -C, and -X [46], producing dis-
tinct protein products, which can form homo- or het-
erodimers [47]. In addition, all four NFI mRNAs can be
differentially spliced to yield a large number of NFI iso-
forms with subtle differences in their transactivation
properties [48,49]. NFI has been reported to repress the
activity directed by the rPARP-1 promoter [39,40]. How-
ever, as NFI was found to be transcriptionally inert by
itself as it possesses no intrinsic activity in the regulation
of the rPARP-1 promoter, its negative influence was sug-
gested to result from the fact that it competes with Sp1 for
the availability of a promoter composite element that
bears overlapping target sites for both these transcription
factors [40]. Consequently, by exploiting either the syner-
gistic or antagonistic effects of the transcription factors
they bind to respectively over-activate or down-regulate
transcription, the combination of regulatory elements
that constitute the PARP-1 promoter provides an efficient
way of fine-tuning its expression in different cellular con-
texts.
As with many other nuclear proteins, both Sp1 and NFI
can be subjected to post-translational modificationsBMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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through mechanisms such as phosphorylation and/or gly-
cosylation [50,51]. However, neither of these transcrip-
tion factors, which are both required to ensure proper
transcription of the PARP-1 gene, has been shown to be
also subjected to poly(ADP-ribosyl)ation by PARP-1. In
the present study, we examined both the expression and
DNA binding properties of Sp1 and NFI in embryonic
fibroblasts cultured from normal mice that express the
intact, wild-type PARP-1 protein (PARP-1+/+), or from
PARP-1 knockout mice (PARP-1-/-) that are devoided of
any PARP-1 enzymatic activity [52]. We demonstrated
that PARP-1 physically associates, through protein-pro-
tein interaction, with Sp1 but not Sp3 or NFI in immuno-
precipitation assays. Sp1 was also found to be a target of
PARP-1 as addition of PAR to this transcription factor
could be demonstrated. Preventing poly(ADP-ribo-
syl)ation of Sp1 in the PARP-1 deficient knockout cells
also resulted in a substantial increase in the activity
directed by rat PARP-1 promoter, a clear indication that
addition of PAR to Sp1 reduces its transactivation proper-
ties in vivo.
Results
Expression and DNA binding of Sp1, Sp3 and NFI in PARP-
1+/+ and PARP-1-/- cells
To investigate whether suppression of PARP-1 activity
would result in alterations in the level of expression and/
or the DNA binding activity of the transcription factors
that are critical for the transcription of the PARP-1 gene,
crude nuclear extracts were prepared from embryonic
fibroblast cell lines derived from both normal (PARP-1+/
+) and PARP-1 knockout mice (PARP-1-/-) [52]. These
extracts were then used to monitor the expression and
DNA binding activity of transcription factors (Sp1, Sp3
and NFI) that have been reported to play critical functions
in PARP-1 gene transcription [37,39-41,53,54]. As
expected, PARP-1+/+ fibroblasts appropriately expressed
the PARP-1 protein whereas no PARP-1 expression could
be detected in the PARP-1-/- cell line (Figure 1). Whereas
no alteration was observed in the level of Sp3 expression
between both types of cells, a dramatic reduction was
however observed for Sp1 in PARP-1-/- cells. NFI, which
yields multiple bands in the EMSA due to the fact that dif-
ferent isoforms have been recognized for this transcrip-
tion factor, primarily appeared as a fast migrating protein
species when nuclear extracts from PARP-1+/+ cells are
used in Western blotting (* in Figure 1). However, the
electrophoretic mobility of this NFI protein species was
considerably reduced in PARP-1-/- cells (arrowhead in Fig-
ure 1), suggesting that NFI is either subjected to post-
translational modifications or to the differential expres-
sion of a specific isoform that is distinct from that seen in
PARP-1+/+ cells.
In order to verify whether both the decrease in Sp1 expres-
sion and change in the mobility of the NFI protein also
resulted in a corresponding alterations in the DNA bind-
ing of both transcription factors, EMSA experiments were
conducted. Crude nuclear proteins from both the PARP-
1+/+ and PARP-1-/- cells were therefore incubated with 5'-
end labeled, double-stranded oligonucleotides bearing
the high affinity-binding site for either Sp1 or NFI. DNA-
protein complexes were resolved on native polyacryla-
mide gels and their position revealed by autoradiography.
As shown on Figure 2A, both the NFI and Sp1 labeled
probe yielded the appropriate DNA-protein complexes
corresponding to the binding of both factors to their
respective target sequence when incubated with the
extract from PARP-1+/+ cells. However, and consistent with
the results of the Western blot analyses shown on Figure
1, formation of both complexes was considerably reduced
when the Sp1 and NFI labeled probe were incubated with
Expression of PARP-1, Sp1, Sp3 and NFI in PARP-1+/+ and  PARP-1-/- cells Figure 1
Expression of PARP-1, Sp1, Sp3 and NFI in PARP-1+/+ 
and PARP-1-/- cells. Crude nuclear extracts (10 μg) from 
both PARP-1+/+ and PARP-1-/- cells were examined in West-
ern blot using antibodies directed against PARP-1, Sp1, Sp3 
and NFI. The position of the 120 kDa and 60 kDa proteins 
used as molecular mass markers is indicated. The asterisk 
indicates the position of the typical NFI complex whereas the 
arrowhead designates NFI complexes with a reduced elec-
trophoretic mobility that predominated in the extract from 
PARP-1-/- cells. Data of one from three similar experiments 
are presented.BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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the extract from PARP-1-/- cells. Formation of the Sp1
complex observed with the extracts from both the PARP-
1+/+ and PARP-1-/- cells was found to be specific as it was
entirely competed off by as little as a 100-fold molar
excess of the unlabeled Sp1 oligomer, but not at all by the
unrelated NFI site (Figure 2B). The reduced binding of
Sp1 in PARP-1-/- cells did not result from changes in the
affinity of Sp1 toward its GC-rich target site but rather
from a decrease in its expression at the protein level as a
corresponding reduction was also observed for this tran-
scription factor in Western blot analysis (Figure 1). Iden-
tical results were observed also for the NFI complex whose
formation was competed by the NFI but not the Sp1 oli-
gomers (Figure 2C).
The identity of the proteins that yielded the shifted com-
plexes using the Sp1 labeled probe was further investi-
gated by supershift analyses in EMSAs using antibodies
directed against either Sp1 and Sp3, two closely related
transcription factors from the same family [42]. As shown
on Figure 2D, the Sp1 Ab strongly reduced the migration
of the complex with the lowest electrophoretic mobility
but had no influence on the weaker, faster migrating com-
plex. On the other hand, the antibody against Sp3 only
slightly decreased the electrophoretic mobility of the slow
complex but entirely competed the fast migrating one.
Incubation of both the Sp1 and Sp3 Abs together entirely
supershifted both complexes, using the nuclear extracts
from both the PARP-1+/+ and PARP-1-/- cell lines. Both
antibodies yielded super-shifted complexes (SSC) corre-
sponding to the signal yielded by the Ab-Sp1(Sp3)-DNA
complex. These results indicate that the slow migrating
complex is made up of both Sp1 and Sp3 bound to the
labeled probe (primarily Sp1) whereas the faster migrat-
ing complex is entirely made up of Sp3. A similar experi-
ment was also conducted on the DNA-protein complex
yielded by the incubation of both the PARP-1+/+  and
PARP-1-/- nuclear extracts with the NFI probe. As pre-
sented on Figure 2D, addition of the NFI Ab reduced the
electrophoretic mobility of the NFI complex from both
the PARP-1+/+ and PARP-1-/- protein extracts and yielded a
new super-shifted complex resulting from the recognition
of the NFI-DNA complex by the NFI Ab. We therefore con-
clude that expression and DNA binding of both Sp1 and
NFI is severely reduced in the PARP-1 knockout (PARP-1-
/-) cells.
To eliminate the possibility that a widespread suppression
of all transcription factors might have accounted for the
drop in both Sp1 and NFI expression in PARP-1-/- knock-
out cells, we investigated the expression and DNA binding
properties of transcription factors unrelated to the tran-
scription of the PARP-1 gene. Double-stranded oligonu-
cleotides bearing the target sites for the transcription
factors AP-1, E2F1 and STAT-1 were therefore 5'-end
labeled and used in EMSA in combination with nuclear
extracts obtained from both PARP-1+/+ and PARP-1-/- cells.
As shown on Figure 3, whereas binding of AP-1 to its pro-
totypical target site was entirely abolished in PARP-1-/-
cells, that of both E2F1 and STAT-1 remained unaffected
by the lack of PARP-1 expression in the knockout cells.
Western blot analyses indicated that the lack of AP-1 bind-
DNA binding properties of Sp1/Sp3 and NFI in PARP-1+/+ and  PARP-1-/- cells Figure 2
DNA binding properties of Sp1/Sp3 and NFI in 
PARP-1+/+ and PARP-1-/- cells. (A) EMSA analysis of Sp1/
Sp3 and NFI. Crude nuclear proteins (5 μg) from both PARP-
1+/+ and PARP-1-/- cells were incubated with a 5' end-labeled 
probe bearing the high affinity binding site for either Sp1 
(left) or NFI (right). Formation of DNA/protein complexes 
was then monitored by EMSA on an 8% (Sp1) and 10% (NFI) 
native polyacrylamide gel and their position revealed through 
autoradiography. The position of both the Sp1/Sp3 and NFI 
DNA-protein complexes are shown, as well as that of the 
free probe (U). P: labeled probe alone. (B) Sp1 competition 
experiment in EMSA. The Sp1 labeled probe used in panel A 
was incubated with nuclear proteins (5 μg) from both PARP-
1+/+ and PARP-1-/- cells in the presence of either no (-) or 
100- and 500-fold molar excesses of unlabeled competitor 
oligonucleotides (either Sp1 or NFI). Formation of DNA/
protein complexes was then monitored by EMSA on an 8% 
native gel. (C) NFI competition experiment in EMSA. Same 
as in panel B except that the NFI double-stranded oligonucle-
otide was 5'-end labeled and used as probe for the assay. (D) 
Supershift experiment in EMSA. Crude nuclear proteins from 
both PARP-1+/+ and PARP-1-/- cells were incubated with the 
either the Sp1 (5 μg proteins were used) or NFI (10 μg pro-
teins were used) labeled probe in the presence of either no 
(-), or 2 μl of a polyclonal antibody directed against Sp1 
(Sp1Ab) or Sp3 (Sp3Ab) and added either individually or in 
combination (Sp1+Sp3Ab) (left), or with a polyclonal anti-
body directed against NFI (right). Formation of both the Sp1/
Sp3 and NFI complexes, as well as their corresponding 
supershifted complexes (SSC) is indicated. P: labeled probe 
alone; U: unbound fraction of the labeled probe.BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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ing resulted from the absence of c-jun in the PARP-1-/-
cells, whereas no change was observed in the expression of
both the E2F1 and STAT-1 proteins. Therefore, the reduc-
tion in the expression and DNA binding of both Sp1 and
NFI is closely linked to the lack of functional PARP-1 in
the PARP-1-/- knockout cells and is not merely the conse-
quence of a general shutdown of gene expression that
might have occurred in these cells.
PARP-1 physically interacts with Sp1
As PARP-1 has been shown to physically interact with
many nuclear proteins of which some are transcription
factors, we then wished to determine whether any of Sp1,
Sp3 or NFI could represent a target for PARP-1 in vitro. Sp1
was therefore immunoprecipitated from nuclear extracts
prepared from PARP+/+ and PARP-/- cells using the Sp1
Ab (sc-59) and the immunoprecipitated proteins ana-
lyzed on Western blot with Abs directed against either Sp1
or PARP-1 (C-2-10). As shown on Figure 4A, Sp1 was very
efficiently immunoprecipitated with the Sp1 Ab as it
could be detected in the extracts from both the PARP-1+/+
and PARP-1-/- cells. As expected, a much weaker Sp1 signal
was obtained with the PARP-1-/- nuclear extract. Western
blotting the Sp1-immunoprecipitated proteins with the
PARP-1 Ab revealed clearly the presence of PARP-1 in the
extract from PARP-1+/+ cells but not in that from PARP-1-/
- cells, suggesting that indeed, Sp1 and PARP-1 can physi-
cally interact with each other. As expected, no signal was
observed when either protein A-Sepharose (Ctl-) or a rab-
bit IgG Ab were added as negative controls to the extract
in the absence of Sp1 Ab. Blotting of the membrane with
the LP-9610 Ab against PAR revealed the presence of two
poly(ADP-ribosyl)lated proteins in the extract from
PARP-1+/+ but not PARP-1-/- cells: a more intense band
with an electrophoretic mobility identical to that corre-
sponding to PARP-1, and a weaker, faster-migrating band
with a mobility on gel identical to that expected for Sp1.
Again, both negative controls (protein A-Sepharose (Ctl-)
and rabbit IgG Ab) yielded no signal at a position similar
to those seen with the Sp1 Ab. As a positive control, total
proteins were prepared from E. coli cells transformed with
a recombinant plasmid that encodes high levels of a fully
functional, truncated PARP-1 [55], and used in Western
blotting. As shown on Figure 4A, blotting of the bacteri-
ally produced recombinant PARP-1 protein with the PAR
Ab LP-9610 revealed a smear that is typical of PAR-modi-
fied proteins [56].
To further validate the results from the Sp1 immunopre-
cipitation, the reverse experiment was conducted by first
immunoprecipitating the PARP-1 associated proteins
from total protein extracts prepared from PARP-1+/+ and
PARP-1-/- cells using the F1–23 Ab against PARP-1. We
selected this Ab primarily because it is much more effi-
cient in immunoprecipitating PARP-1 than the C-2-10 Ab.
The transcription factors Sp1, Sp3 and NFI could be
detected easily by Western blot in the total extracts from
both PARP-1+/+ and PARP-1-/- cells prior to immunopre-
DNA binding and expression of the transcription factors AP- 1, E2F1 and STAT-1 in PARP-1+/+ and PARP-1-/- cells Figure 3
DNA binding and expression of the transcription fac-
tors AP-1, E2F1 and STAT-1 in PARP-1+/+ and PARP-
1-/- cells. (A) EMSA analysis. Crude nuclear proteins (5 μg) 
from both PARP-1+/+ and PARP-1-/- cells were incubated with 
a 5' end-labeled probe bearing the high affinity binding site for 
AP-1, E2F1 and STAT-1. Formation of DNA/protein com-
plexes was then monitored by EMSA on an 8% gel as detailed 
in Figure 2. The position of the AP-1, E2F1 and STAT-1 
DNA-protein complexes is shown, as well as that of the free 
probe (U). P: labeled probe alone. (B) Coomassie blue stain-
ing of the protein samples used for conducting both the 
EMSA (panel A) and the Western blot experiment (panel C). 
One protein band present in both extract was randomly 
selected and its intensity determined by densitometric analy-
sis in order to precisely calibrate the protein concentration 
used for the assays. (C) Nuclear extracts (10 μg) from both 
PARP-1+/+ and PARP-1-/- cells were examined in Western 
blot as in Figure 1 using antibodies directed against E2F1, 
STAT-1 and the AP-1 subunit c-jun. The position of the near-
est molecular mass markers is indicated (60 kDa and 85 
kDa).BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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cipitation of PARP-1 (T.E. in Figure 4B). Immunoprecipi-
tation of PARP-1 with the F1–23 Ab and further Western
blotting of the precipitated proteins revealed clearly that
the F1–23 Ab was efficient in immunoprecipitating PARP-
1 in the extract from PARP-1+/+ but not from PARP-1-/-
cells. In addition, Sp1 could also be revealed in the immu-
noprecipitate using the sc-59 Ab. On the other hand, the
Abs against Sp3 and NFI could not detect any of these
transcription factors in the PARP-1 immunoprecipitate.
We therefore conclude that Sp1 but not Sp3 nor NFI asso-
ciate physically with PARP-1 in vitro through protein-pro-
tein interactions.
PARP-1 enzymatic activity is not required for its 
interaction with Sp1
We next examined whether the interaction between PARP-
1 and Sp1 would be affected by the activation state of the
PARP-1 enzyme in wild-type PARP-1+/+ cells. Sp1 was
therefore immunoprecipitated in nuclear extracts from
PARP-1+/+ cells that have been grown either alone (con-
trol), or in the presence of hydrogen peroxide (H2O2) to
induce PARP-1 activity. Exposure of cells to H2O2 in vivo
did not prevent nor improve the interaction between Sp1
and PARP-1 (Figure 5). Similarly, preventing PARP-1
activity by culturing PARP-1+/+ cells in the presence of the
PARP-1 inhibitor PJ34 did not alter the Sp1/PARP-1 inter-
action in vivo. The IP experiments shown above were all
conducted on extracts obtained from PARP-1+/+ cells in
the absence of any added DNA. Although we could not
detect any contaminating genomic DNA when increasing
Influence of PARP-1 activity on the co-immunoprecipitation  of PARP-1 by Sp1 Figure 5
Influence of PARP-1 activity on the co-immunopre-
cipitation of PARP-1 by Sp1. Nuclear proteins (300 μg) 
from PARP-1+/+ cells grown either alone (control) or in the 
presence of hydrogen peroxide (H2O2), PJ34 PARP-1 inhibi-
tor, or ethidium bromide were incubated with the Sp1 Ab 
(sc-59) and the Sp1-protein complexes recovered by the 
addition of protein-A-Sepharose. The resulting immunopre-
cipitated proteins were then gel fractionated as in Figure 4 
and Western blotted with antibodies against Sp1 or PARP-1 
(C-2-10). TE: total cell extract that has not been immunopre-
cipitated with the Sp1 Ab. Ctl-: protein A-Sepharose added 
to crude nuclear proteins in the absence of Sp1 Ab and used 
as a negative control. IgG-Ab: normal rabbit IgG incubated 
with nuclear proteins prior to addition of protein A-Sepha-
rose as a negative control.
Co-immunoprecipitation of Sp1 and PARP-1 in protein  extracts from PARP-1+/+ and PARP-1-/- cells Figure 4
Co-immunoprecipitation of Sp1 and PARP-1 in pro-
tein extracts from PARP-1+/+ and PARP-1-/- cells. (A) 
Immunoprecipitation of the Sp1-protein complexes in PARP-
1+/+ and PARP-1-/- nuclear extracts. Crude nuclear proteins 
(300 μg) from both PARP-1+/+ and PARP-1-/- cells were incu-
bated with the Sp1 Ab (sc-59) and the Sp1-protein com-
plexes recovered by the addition of protein-A-Sepharose. 
The resulting immunoprecipitated proteins were then SDS-
gel fractionated before being membrane-transferred and 
Western blotted with antibodies against Sp1, PARP-1 (C-2-
10) and PAR (LP-9610). Ctl-: protein A-Sepharose added to 
crude nuclear proteins in the absence of Sp1 Ab and used as 
a negative control. IgG-Ab: normal rabbit IgG incubated with 
nuclear proteins prior to addition of protein A-Sepharose as 
a negative control. (B) Immunoprecipitation of the PARP-1-
protein complexes in PARP-1+/+ and PARP-1-/- nuclear 
extracts. Same as in panel A except that the immunoprecipi-
tation was conducted using the PARP-1 F-123 Ab. The blot-
ted, PARP-1-immunoprecipitated proteins were then 
analyzed with the PARP-1 (422), Sp1 (sc-59), Sp3 (sc-644), 
and PAR (LP-9610) antibodies. Negative controls (Ctl- and 
IgG-Ab) are as in panel A. TE: total cell extract that has not 
been immunoprecipitated with the PARP-1 Ab.BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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amounts (up to 10 μg) of the extract from the PARP-1+/+
cells are ran on an agarose gel and then stained with ethid-
ium bromide (data not presented), yet the possibility
remained that undetectable traces of genomic DNA might
have been present in our extracts and then contributed to
the interaction between both Sp1 and PARP-1 by provid-
ing potential target sites to which Sp1 would first interact
with. Therefore, in order to avoid any possible interfer-
ence by any traces of contaminating genomic DNA, we
repeated the IP experiment with the Sp1 antibody, but this
time added ethidium bromide to the reaction mixture
prior to the addition of the primary Abs in order to avoid
any possible interaction of Sp1 with any putative target
sites in DNA. As shown on Figure 5, the presence of ethid-
ium bromide did not alter in any way the co-immunopre-
cipitation of PARP-1 along with Sp1 in PARP-1+/+ cells.
Most interestingly, over-activation of PARP-1 activity in in
vitro PARP assays not only resulted in a massive addition
of PAR to PARP-1, as revealed by the dramatic change in
its electrophoretic mobility, but also entirely abolished
interaction with Sp1 (Figure 5) therefore indicating that
addition of PAR to PARP-1 beyond a certain level also
interferes with its ability to bind Sp1.
Sp1 is a target of PARP-1 enzymatic activity
As the PAR Ab revealed the presence of a poly(ADP-ribo-
syl)ated protein in the Sp1 immunoprecipitate that has
the same electrophoretic mobility as that of Sp1, we there-
fore used in vitro PARP assays to determine whether PARP-
1 could add PAR to this transcription factor. Western blot
analyses were conducted to monitor both the PARP-1 and
Sp1 proteins, as well as their poly(ADP-ribosyl)ation by
the addition of PAR. PARP-1 alone possesses no intrinsic
activity in the absence of its substrate NAD+ (Figure 6A,
lane 1). However, the addition of 200 μM NAD+ was suf-
ficient to turn on PARP-1 activity, which then added PAR
to itself (Figure 6A; PARP-1Mod: bottom panel) through
its automodification domain. Automodification of PARP-
1, which dramatically changed its electrophoretic mobil-
ity in SDS-PAGE (yielding a smear on the gel; Figure 6A,
lane 2: top panel), was entirely prevented when the PARP-
1 inhibitor PJ34 was added to the reaction mix (Figure 6A,
lane 3). As shown on lane 4, recombinant Sp1 is initially
free of PAR. However, upon incubation with both PARP-
1 and NAD+, a faint band with a molecular mass corre-
sponding to Sp1 (Sp1Mod) could be detected with the
PAR Ab just beneath the signal (smear) corresponding to
the automodified PARP-1 (Figure 6A, lane 5: bottom
panel). Again, the addition of the PJ34 PARP-1 inhibitor
entirely prevented the addition of PAR to both proteins
(PARP-1 and Sp1; lane 6). In order to demonstrate the
specific addition of PAR to both Sp1 and PARP-1, both
recombinant proteins were incubated together along with
NAD+ as in lane 5. Protein samples were electrophoresed
on SDS-PAGE and transferred on membranes as above.
The PAR covalently linked onto the automodified PARP-1
and Sp1 proteins transferred on the membranes was then
erased by incubation with PARG. As shown on Figure 6A
(lane 8: bottom panel), no polymer could be detected by
the PAR Ab on both the PARP-1 and Sp1 proteins upon
exposure to PARG. The fact that the proteins were first
fractionated on the SDS gel and membrane-transferred
prior to the treatment with PARG explains the lack of any
PARP-1-dependent poly(ADP-ribosyl)ation of Sp1 in vitro Figure 6
PARP-1-dependent poly(ADP-ribosyl)ation of Sp1 in 
vitro. (A) Recombinant Sp1 protein was incubated in reac-
tion buffer either alone (lane 4) or with purified bovine 
PARP-1 (1 unit) in the presence of 200 μM NAD+ (lane 5). 
The reaction mixture was subjected to Western blot analysis 
with the PARP-1 (C-2-10), Sp1 (sc-59) and PAR (LP-9610) 
antibodies. When indicated, the PARP inhibitor PJ34 was 
added to the reaction mixture with purified PARP-1 alone 
(lane 3) or in the presence of recombinant Sp1 (lane 6). 
When indicated, samples from the in vitro PARP assay were 
electrophoresed and electrotransfered onto nitrocellulose 
membranes. The PAR covalently linked onto the automodi-
fied PARP-1 and Sp1 proteins was then erased by incubation 
with PARG and the proteins analyzed by Western blotting 
with the same antibodies as detailed above (lane 8). Lane 1: 
PARP-1 alone; lane 2: PARP-1 incubated with NAD+; lane 3: 
same as in lane 2 plus PJ34; lane 7: same as in lane 5 but incu-
bated in PARG buffer without addition of PARG-1. The posi-
tion of modified PARP-1 (PARP-1Mod) and Sp1 (Sp1Mod) is 
indicated (left) along with the appropriate molecular mass 
marker (right). (B) Recombinant Sp1 was incubated in reac-
tion buffer containing 200 μM NAD+ and nicked DNA either 
alone (+SP1; lane 3) or with purified bovine PARP-1 (1 unit) 
(+Sp1/PARP-1; lane 4). A sample (16 μl) from the reaction 
mixture was then incubated with the 5'-end labeled Sp1 oli-
gonucleotide and formation of DNA-protein complexes 
monitored by EMSA as in Figure 2. As a control, the PARP-1 
inhibitor PJ34 was added to the reaction mixture containing 
PARP-1/NAD+/Sp1 (+Sp1/PARP-1/PJ34; lane 5). Lane 1: 
labeled probe alone in reaction mix (P); Lane 2: labeled probe 
incubated in buffer D with PARP-1 but in the absence of 
NAD and Sp1 (+PARP-1). The position of both the Sp1 com-
plex (Sp1) and the free probe (U) is indicated.BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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change in the electrophoretic mobility of PARP-1 on gel
(lane 8, top panel), which again appears as a smear due to
the initial addition of PAR.
We then monitored whether addition of PAR to Sp1 in
vitro would alter its DNA binding properties in EMSA. As
shown on Figure 6B (lane 3), the recombinant Sp1 pro-
tein yielded the typical Sp1 DNA-protein complex upon
addition of the Sp1 labeled probe when incubated with
the reaction mix containing both NAD+ and nicked DNA
in the absence of PARP-1. However, addition of PARP-1 to
the reaction mix severely reduced binding of Sp1 to its
corresponding labeled probe (by approximately 71%, as
revealed by densitometric analysis of the labeled DNA-
protein complex)(Figure 6B, lane 4). The further addition
of the inhibitor PJ34 prevented the addition of PAR by
PARP-1 and entirely restored the binding properties of
Sp1 (Figure 6B, lane 5). We next tested whether the addi-
tion of PAR to endogenous Sp1 would also reduce its
DNA binding properties in vivo in crude nuclear extracts
prepared from PARP-1+/+ cells grown in the presence of
H2O2 to activate PARP-1 in these cells. A dramatic reduc-
tion in the binding of Sp1 to its DNA target probe was
observed in EMSA when PARP-1 activity was increased in
H2O2-treated cells (Figure 7A, compare lane 3 with lane
2). This H2O2-dependent reduction in Sp1 binding was
entirely abolished when H2O2-treated cells were also
added the PARP-1 inhibitor PJ34 (PJ34+ H2O2; Figure 7,
lane 5). Western blot analyses provided evidence that nei-
ther of these treatments (addition of PJ34 or H2O2) had
any influence on the PARP-1 or Sp1 protein level (Figure
7B), a further indication that the reduced binding of Sp1
in H2O2-treated cells can be accounted for by post-trans-
lational addition of PAR to Sp1 by PARP-1. Monitoring
the addition of PAR to the PARP-1 protein with the 10-H
antibody against the polymer confirmed that exposing
PARP-1+/+  cells to the PARP-1 inducer H2O2  indeed
resulted in the automodification of endogenous PARP-1,
that again appears as a smear in Western blotting (PAR;
Figure 7B).
There are many potential hypotheses that may explain
why expression of both endogenous Sp1 and PARP-1 does
not change upon incubation with PJ34. However, and as
the cells treated with PJ34 were harvested only 18 hours
later, we initially thought they might not have had suffi-
cient time to alter their pattern of protein expression. We
therefore conducted a new set of experiments but selected
primary cultures of human skin keratinocytes (HSKs) as a
cellular model for PARP-1 expression rather than PARP-
1+/+ cells. HSKs were first exposed to H2O2 in order to
trigger activation of endogenous PARP-1 in these cells,
and then harvested at various periods of times (4-, 24- and
72 hours) for further analysis of Sp1 DNA binding and
both Sp1 and PARP-1 expression at the protein level. As
an additional control, cells triggered with H2O2 were also
added PJ34 at each selected time-point prior to harvesting.
Neither H2O2 nor H2O2+PJ34 had any significant influ-
In vivo influence of PARP-1 activity on the expression and  DNA binding of Sp1 Figure 7
In vivo influence of PARP-1 activity on the expression 
and DNA binding of Sp1. (A) Nuclear proteins (5 μg) 
from PARP-1+/+ cells grown alone (-; lane 2) or in the pres-
ence of H2O2 (lane 3) or PJ34 (lane 4), added either individu-
ally or in combination (PJ34+ H2O2; lane 5), were incubated 
with the Sp1 labeled probe and formation of DNA/protein 
complexes monitored by EMSA on a 8% native polyacryla-
mide gel as in Figure 2. The position of both the Sp1 and Sp3 
DNA-protein complexes are shown, as well as that of the 
free probe (U). P: labeled probe alone (lane 1). (B) The 
extracts used in panel A were SDS-gel fractionated before 
being membrane-transferred and Western blotted with anti-
bodies against Sp1 (sc-59), PARP (C-2-10) and PAR (10-H). 
The position of the appropriate molecular mass markers (60-
, 120-, and 190 kDa) is indicated. (C) Nuclear proteins (5 μg) 
from primary cultures of HSKs grown for various periods of 
time (4-, 24- and 72 h) either alone (-; lanes 1, 4 and 7), or in 
the presence of H2O2 (lanes 2, 5 and 8) or both H2O2 and 
PJ34 (PJ34+ H2O2; lanes 3, 6 and 9), were incubated with the 
Sp1 labeled probe and formation of DNA/protein complexes 
monitored by EMSA on a 8% native polyacrylamide gel as in 
panel A. (D) The extracts used in panel C were analyzed by 
Western blotting with antibodies against Sp1 (sc-59), PARP 
(C-2-10) and β-actin (CLT9001). Densitometric analyses of 
the band intensities was determined for both the Sp1 and 
PARP-1 proteins and normalized to that measured for β-
actin. Values are shown below each corresponding track.BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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ence on the DNA binding properties of Sp1 at 4 h of treat-
ment (Figure 7C; compare lane 1 with lane 2), which is
also supported by the weak influence of these reagents on
both Sp1 and PARP-1 protein expression in Western blot
(Figure 7D). However, challenging PARP-1 activity
through exposure of HSKs to H2O2 not only reduced the
binding capacity of Sp1 (and to some extend, Sp3 as well)
in these cells at 24 and 72 h (Figure 7C) but also trans-
lated into a reduction in the expression of both PARP-1
and Sp1 proteins (Figure 7D). Most interestingly, the
H2O2-dependent reduction in the DNA binding of both
Sp1 and Sp3 was not solely reverted by the further addi-
tion of the PARP-1 inhibitor PJ34 but was even consider-
ably improved at 72 h (Figure 7C; compare lane 9 with
lane 8). This dramatic increase in Sp1 DNA binding also
translated in an increased expression of Sp1 at the protein
level, which nearly doubled upon addition of the PJ34
inhibitor (ratio of the Sp1/β-actin signal of 0.111 with
H2O2 and 0.206 with H2O2+PJ34, as revealed by densit-
ometric analysis of each protein band). We therefore con-
clude that PARP-1-dependent addition of PAR to Sp1
reduces its DNA binding properties and thereby alter the
efficiency with which it can transcribe its target genes,
which comprise the PARP-1 gene besides from the Sp1
gene itself.
Influence of poly(ADP-ribosyl)ation on the activity 
directed by the rPARP-1 promoter
Most of the activity directed by the PARP-1 gene promoter
was shown to rely essentially on the recognition of multi-
ple PARP-1 promoter target sites by members of the Sp1
family [37,38,41]. Of them, Sp1 accounted for most of the
positive influence exerted on this promoter [54]. We dem-
onstrated above that both expression and DNA binding of
Sp1 is considerably decreased in PARP-1-/- cells. We there-
fore examined whether this decrease would also translate
into a reduced PARP-1 promoter activity upon transfec-
tion of PARP-1-/- cells with a recombinant construct bear-
ing the CAT reporter gene fused to the basal promoter
from the rat PARP-1 gene that has its three Sp1 target sites
(F2, F3 and F4) either kept intact (in pCR3) or mutated
(in pCR3F2/F3/F4m) [37]. Unexpectedly, transfection of
the pCR3 construct into PARP-1-/- cells yielded CAT activ-
ities approximately 4-fold higher than in PARP-1+/+ cells
(Figure 8A). Consistent with these results, exposing pCR3-
transfected PARP-1+/+cells that express the wild type
PARP-1 protein to the PARP-1 inhibitor PJ34 resulted in a
near 8-fold increase in basal PARP promoter activity while
it had no influence in PARP-1-/- cells. Mutating all three
Sp1 sites from the PARP-1 promoter (in pCR3F2/F3/F4m)
dramatically reduced basal promoter activity and entirely
suppressed induction of PARP-1 promoter function in
PARP-1-/- cells. Suppression of PARP-1 activity with PJ34
in PARP-1+/+ cells had no influence on the activity directed
by pCR3F2/F3/F4m suggesting that the regulatory influ-
ences of PARP-1 on its own promoter are mediated
through alteration of Sp1.
As the trans-activating properties of the PAR-free Sp1 is
increased in PARP-1-/- cells, we then wished to determined
whether the transcriptional activity directed by other
gene's promoter reported to be under the regulatory influ-
ence of this transcription factor would also be similarly
affected by the lack of PARP-1 activity. We recently
reported that transcription of the human α5 integrin sub-
unit gene was under the positive regulatory influence of
both a proximal and a distal Sp1 site in primary cultures
of rabbit corneal epithelial cells [57,58]. We therefore
used a recombinant construct that bear the CAT reporter
gene fused to a truncated version of the α5 promoter that
contain only the proximal Sp1 site (-92α5CAT) for con-
ducting this experiment. In addition, and as the GC-rich
promoter from the human α6 integrin subunit gene was
also reported to be positively regulated by Sp1 [59,60], a
rPARP-1 promoter activity in PARP-1+/+ and PARP-1-/- cells Figure 8
rPARP-1 promoter activity in PARP-1+/+ and PARP-1-
/- cells. (A) The recombinant plasmids PCR3 and PCR3F2/F3/
F4m were transfected into both PARP-1+/+ and PARP-1-/- 
cells grown with or without the PARP-1 inhibitor PJ34. CAT 
activities were measured and normalized to the amount of 
hGH secreted into the culture medium. Values are expressed 
as ((%CAT activity/100 μg proteins)/ng hGH). Asterisks (*) 
indicate CAT activities from cells exposed to PJ34 that are 
statistically different from those measured when cells are 
transfected with pCR3 in the absence of inhibitor whereas † 
corresponds to CAT activities in PARP-1-/- cells that are sta-
tistically different from those measured in PARP-1+/+ cells (P 
< 0.005; paired samples, t-test). S.D. is also provided. (B) The 
plasmids PCR3, -92α5CAT and α6–84 were transfected into 
both PARP-1+/+ and PARP-1-/- cells and CAT activity 
(expressed as the ratio of CAT activity from PARP-1-/- cells 
over that measured in PARP-1+/+ cells (considered as 100%)) 
measured and normalized as detailed above. Asterisks (*) 
correspond to CAT activities in PARP-1-/- cells that are sta-
tistically different from those measured in PARP-1+/+ cells (P 
< 0.005; paired samples, t-test).BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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recombinant construct that has the CAT gene fused to the
basal promoter from the α6 gene (α6–84) was also used
in these assays. The -92α5CAT and α6–84 constructs were
therefore transfected into both the PARP-1-/- and PARP-1+/
+ cell lines and CAT activity determined and normalized.
As shown on Figure 8B, transfection of the PARP-1 pro-
moter-bearing construct pCR3 yielded a CAT activity that
was more than 4-times more elevated in PARP-1-/- than in
PARP-1+/+ cells (which is expressed as the ratio of the
activity measured in PARP-1-/- over that from PARP-1+/+
cells). Interestingly, transfection of both the α5 and α6
promoter constructs also yielded increased CAT activities
in PARP-1-/-  cells (2.4- and 2.6-fold increases, respec-
tively), indicating that the altered regulatory influence
resulting from the lack of PAR addition to Sp1 in PARP-1-
/- cells is not merely restricted to the PARP-1 promoter but
also affect transcription of other Sp1-responsive genes as
well.
Discussion
The ability of the PARP-1 protein to interact with a variety
of nuclear-located transcription factors and thereby alter
their regulatory function toward the target genes that they
regulate is certainly among the most important of the
many functions PARP-1 may play as it will ultimately alter
the pattern of genes expressed by any given cell. Although
an increasing number of such transcription factors are
being reported every year, yet only a few of them have
been shown to be post-translationally modified by PARP-
1. Here we show that PARP-1 physically associates with
the positive transcription factor Sp1 and reduces its trans-
activating properties by the catalytic addition of PAR to
this protein. We demonstrate that such a post-transla-
tional alteration of Sp1 not only reduces the transcription
of the PARP-1 gene itself (as the lack of PARP-1 activity in
PARP-1-/- cells also translates into a more than 4-fold
increase in PARP-1 promoter function, a result consistent
with those reported by Soldatenkov et al. [19]), but also
that of other Sp1-responsive genes, for instance those
encoding the human integrin subunits α5 and α6. Based
on the fact that the average branching frequency of the
PAR is approximately one branch per linear section of 20–
50 units of ADPr [61-63], and that ADPr units have a
molecular mass of 577 Daltons, we can assume that PAR
branching will translate in an increase of at least 11.5 kDa
in the molecular mass of the acceptor protein. The
unchanged apparent electrophoretic mobility of Sp1 in
Western blot suggests that branching of ADPr units is
however unlikely to occur. This is consistent with
poly(ADP-ribosyl)ation of other transcription factors,
namely RAP30/RAP74 subunits of TFIIF [23]. An analysis
of the 24 potential poly(ADP-ribosyl)ation sites (glutamic
acids residues)in Sp1 (Accession no NP_612482) reveals
that 8 of them are localized within the first 140 amino
acids (N-terminal) whereas 12 are localized at the C-ter-
minal end of the protein. Most of the sites are in
hydrophilic portions of the protein (20 out of 24) and
therefore available to accept PAR. The two last sites at
position E752 and E757 are in an hydrophobic portion
and might not be readily modified by PAR. Modification
by PAR anywhere on the protein may induce its desorp-
tion from DNA. However, two potential sites (E672 and
E690) are localized within the second and third Zn finger
of Sp1, respectively. The specific targeting of these sites
may be critical in negatively regulating the function of Sp1
on specific DNA sequence.
Sp1 modification by PAR alters the expression of the
PARP-1 gene because of the presence of at least five dis-
tinct target sites for this transcription factor in the PARP-1
gene promoter [37]. Besides its action on Sp1, PARP-1 has
also been reported to regulate the transcription of its own
gene through other regulatory mechanisms that are most
likely related to the presence of secondary structures in
DNA. Indeed, it has been shown that the DBD of PARP-1
can repress PARP-1 gene transcription by interacting
directly with hairpin-like structures present in the pro-
moter of the human PARP-1 gene [19]. Although these
results may appear contradictory at first sight to those we
report in this study, yet the possibility remains that the
PARP-1 truncated version they used might have caused
repression of the PARP-1 promoter through the recruit-
ment of other transcription factors rather than through a
direct action of PARP-1 on Sp1. For instance, PARP-1 has
been reported to physically interact with the transcription
factors TEF-1, B-MYB and AP-2 [15,16,25,26,64]. Interest-
ingly, all three transcription factors have been shown to
function not only as activators but also as repressors of
gene transcription [65-69]. Besides, the two most likely
hairpin-like structures in the human PARP-1 promoter
have been shown to be present at quite a distance from the
Sp1 target sites-bearing basal promoter (from nt -325 to -
290 and -418 to -403). It is also worth mentioning that
mutation of all three Sp1 sites contained in the rPARP-1
basal promoter entirely suppressed the induction of
PARP-1 promoter activity in PARP-1-/- cells, a clear evi-
dence that the PARP-1 negative influence on its own pro-
moter-driven transcription is entirely dependent on
altering Sp1 binding at the rPARP-1 promoter.
Addition of PAR to transcription factors can either pro-
mote or reduce their affinity toward their corresponding
sites in DNA. It has been shown that the DNA binding
properties of a few transcription factors, notably YY-1,
NFkB, CREB, the TFIID subunit TBP, and presumably Sp1,
was severely reduced in the presence of NAD+ [27]. The
pattern of migration that they obtained for Sp1 on the
EMSA was, however, not typical of that normally observed
for this transcription factor and might have resulted either
from protein degradation of the crude nuclear extractsBMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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used by these authors or from the fact that a transcription
factor other than Sp1 has bound to the GC-rich labeled
probe they used for conducting their EMSA. Sp1 belongs
to a large family of transcription factors, the Sp/KLF fam-
ily, which comprises 25 proteins that all possess the abil-
ity to bind GC- or GT-rich target sites in DNA as all of
them share three similar Zn-fingers as their DNA binding
domain [70]. As no supershift experiments using an anti-
Sp1 antibody were conducted in the study by Oei and
coworkers, care must be taken as to whether Sp1 indeed
was the transcription factor from the HeLa extract that
actually bound their labeled probe in EMSA as the shifted
band might have resulted from the binding of another
member from the Sp/KLF family to the GC-rich labeled
probe they used.
The experiments that we conducted either in vitro, using
purified Sp1, or in vivo, by inducing the PARP-1 activity
with the oxidative reagent H2O2, provided evidence that
addition of PAR to Sp1 not only lowered its positive regu-
latory influence on gene transcription but also its capacity
to physically interact with its high affinity target sites in
DNA. This exposition of cultured cells (for instance HSKs)
to H2O2 also translated in a reduced expression of both
PARP-1 and Sp1 (as Sp1 was reported to regulate the tran-
scription of its corresponding gene through the presence
of multiple, functional GC-rich target sites [71,72]) at the
protein level, a process that could be reverted in a time-
dependent manner by the PARP inhibitor PJ34 (Fig. 7). It
is important to note that PJ34 has a broad range, and
therefore inhibits the activity of not only PARP-1 but
other PARPs as well. This would include PARP-2, a known
DNA-dependent PARP involved in DNA damage response
and repair [73,74]. However, because PARP-1 accounts for
more than 90% of cellular poly(ADP-ribosyl)ation [75], it
makes the contribution of PARP-2, or other PARPs, mar-
ginal on modification of Sp1. Moreover, the use of PARP-
1-/- cells strongly support the in vivo role of PARP-1 in the
modulation of Sp1 activity. That no reduction, but rather
an increase in the expression of Sp1 is seen in PARP-1+/+
cells (Figs. 1 and 2) is rather paradoxical with the results
from the transfection experiments. Yet, the lack of any
PARP-1 influence when all three Sp1 sites from the PARP-
1 promoter-bearing construct PCR3 are mutated is a clear
evidence that the primary action of PARP-1 in wild-type
PARP-1+/+ cells is directed toward this transcription factor.
As an interesting hypothesis, we suggest that in PARP-1
expressing cells, most, if not all Sp1 proteins has been
added PAR to a certain level, which would represent a
remarkable mean for the cell to restrict the otherwise very
powerful trans-activating properties of Sp1 on gene tran-
scription. Although the basal level of Sp1 expression is
decreased in PARP-1-/-  knockout cells whereas that of
other transcription factors, such as Sp3, E2F1 and STAT-1,
remains unaffected, it would however be free of added
PAR and would thus become a much more potent activa-
tor of gene expression. Besides reducing its trans-activat-
ing properties, addition of PAR to Sp1 may also serve
other cellular functions. Sp1 has been recently reported as
particularly sensitive to protein degradation in quiescent,
post-confluent, but not in actively growing primary cul-
tures of rabbit corneal epithelial cells (RCECs) [57]. Mon-
itoring the steady state level of Sp1 in cells grown in the
presence of PARP-1 inhibitors such as 3-AB or PJ34 in cells
grown at a high cell density might prove particularly
informative considering the recent demonstration that
PARP-1 contributes to the activity of the proteasome in
drug-induced, oxydatively damaged nuclear proteins [76-
78]. Abnormally elevated expression and DNA binding of
Sp1, as for many of the Sp/KLF family members to which
belong Sp1 [79], has been recognized as a valuable prog-
nostic marker in both gastric [80-82] and colorectal can-
cers [83]. PARP-1 mediated addition of PAR to Sp1 can
now be viewed as one out of a few other post-translational
modifications, such as glycosylation and phosphoryla-
tion, that the cell may use to modulate the positive regu-
latory influence of Sp1 and thereby contribute to prevent
any given cell to progress toward anchorage-independent,
unregulated cell proliferation, the hallmark of all cancer
cells.
Although the reduced binding of Sp1 in wild-type PARP-
1+/+ cells grown in the presence of the PARP activator
H2O2 (Fig. 7A) is easily explained by the capacity of PARP-
1 to add PAR to this transcription factor, the similar reduc-
tion observed in Sp1 expression (Fig. 1) and DNA binding
(Fig. 2A) between both wild-type PARP-1+/+ and PARP-1-/
- knockout cells remains speculative. However, the recent
cloning of the human Sp1 gene promoter raises interest-
ing possibilities to highlight the influence the lack of
PARP-1 protein might have on the reduced expression of
Sp1 (refer to Fig. 9 for additional details). Indeed, the
basal promoter of the human Sp1 gene was found to bear
target sites for multiple transcription factors, including
NF-Y, AP-2, E2F, C/EBP as well as Sp1 itself [71]. Interest-
ingly, the transcriptional activity directed by both AP-2
and E2F1 was found to be regulated by PARP-1 activity in
cultured cells. PARP-1 apparently exerts a dual regulatory
influence on AP-2α transcription with opposing effects:
the middle region of the PARP-1 protein interacts physi-
cally with AP-2α and enhance its transcription, a situation
postulated to occur under normal circumstances, whereas
the catalytic domain strongly poly(ADP-ribosyl)ates AP-
2α and thereby reduces binding to its DNA target sites, a
temporary shut-off mechanism that might be used during
unfavourable conditions [84]. On the other hand, E2F-1
was not found to be added PAR by PARP-1 but was found
to physically interact with it, which results in an improved
binding of E2F-1 to its DNA target sites and further
enhances its trans-activating properties, and indicatingBMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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that PARP-1 acts as a positive co-factor of E2F-1-mediated
transcription [85]. Although binding of AP-2 to the Sp1
gene promoter could not be demonstrated, E2F was found
to bind and positively influence transcription of that gene
[71]. Therefore, the reduced expression of Sp1 that we
observed in PARP-1-/- knockout cells may simply result
from the reduced transcriptional activity of E2F-1 (and
maybe also of AP-2) as the Sp1 gene has been reported to
be positively regulated in a dose-dependent manner by
this transcription factor [71] (Fig. 9).
Besides Sp1, our results also demonstrated a reduced
expression of the transcription factors AP-1 and NFI in
PARP-1-/- knockout cells relative to wild type in PARP-1+/+
cells, whereas that of others, such as Sp3, E2F1 and STAT-
1 remained unaffected by the lack of PARP-1 activity. That
AP-1 expression and DNA binding is strongly abrogated
in PARP-1 deficient cells is a well documented fact [86-
90]. Indeed, the pharmacological inhibition of PARP-1
activity in 3,4-dihydro-5-[4-(1-piperinidinyl)butoxyl]-
1(2H)-isoquinoline (DPQ)-treated mice entirely abol-
ished the TPA-dependent activation and DNA binding
properties of AP-1 [86]. Inhibition of PARP-1 activity in
rats treated with nicotinamide was found to prevent N-
methyl-N-nitrosourea-induced photoreceptor apoptosis
through a reduction in the expression of the AP-1 subunit
c-jun, a process that was postulated to depend on the inhi-
bition of the JNK/AP-1 signalization pathway [87]. PARP-
1 activity was recently shown to be required for c-jun
phosphorylation, a process that modulate the stability of
AP-1 and determines its DNA binding efficiency [90].
DNA binding of NFI was found to be strongly abrogated
in the PARP-1-/- knockout cells. These alterations in the
DNA binding properties of NFI also correlated with
important changes in the pattern of NFI protein electro-
phoretic mobility on SDS gels that might result either
from the expression of distinct NFI isoforms, or from
post-translational modifications of NFI that may differ
between the wild-type PARP-1+/+ and PARP-1-/- knockout
cells. To our knowledge, no study has ever reported such
a suppression of the NFI DNA binding properties in
PARP-1-/-  knockout cells. We previously demonstrated
that NFI has a negative influence on the activity directed
by the rPARP-1 promoter but not because it possesses any
intrinsic repressor function but rather because it competes
with Sp1 for the availability of a promoter composite ele-
Model of interplay between PARP-1, Sp1 and other transcription factors Figure 9
Model of interplay between PARP-1, Sp1 and other transcription factors. (A) PARP-1 plays a suppressive function 
(indicated by 'T' bars) on the DNA binding properties of Sp1, and indirectly, on its expression as well, by the enzymatic addi-
tion of poly(ADP-ribose) units (PAR) to Sp1. PARP-1 may exert its effect by stimulating the transcriptional properties (indi-
cated by arrows) of both AP-2 and E2F-1 by physically interacting with these transcription factors (and therefore, 
independently of addition of PAR), of which the latter was recognized as a component required to ensure proper transcription 
of the human Sp1 gene. (B) Once PARP-1 is stimulated by DNA damages, post-translational modification of both Sp1 and AP-
2 is increased to the point that their DNA binding properties and thereby, their transcriptional capacity, is considerably 
decreased without significantly altering their level of expression. (C) However, in the absence of PARP-1, addition of PAR is 
abrogated and the transcriptional capacity of Sp1 becomes dramatically increased despite that its overall expression is consid-
erably reduced primarily as a consequence of: i) a reduction in both the expression [112] and the positive transcriptional influ-
ence of E2F1 [85], a property that requires a physical interaction with PARP-1, and ii) a reduced transcriptional activity of AP-
2, which also requires a physical association of this transcription factor with the middle region of PARP-1 [84]. TrC: transcrip-
tional capacity of Sp1; Exp: level of Sp1 expression.BMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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ment that bears overlapping target sites for both these
transcription factors [39,40]. Interestingly, members from
the NFI family have been reported to be as efficient as
repressors [40,91,92] than activators [93,94] of gene tran-
scription. Besides, NFI sites have often been shown to be
located close to, or overlapping with nearby Sp1 sites.
Indeed, NFI was reported to interact with and antagonize
Sp1, which result in the down-regulation of the platelet-
derived growth factor (PDGF)-A gene expression [95]. We
recently reported that a similar interference of Sp1 action
by NFI might also account for the transcriptional repres-
sion of the p21 genes [96]. The physiological significance
of NFI suppression in the PARP-1-/- knockout cells has yet
to be precisely determined, although one would predict
that its suppression would tend to favor the positive influ-
ence of the potentiated action of Sp1 that results from its
lack of PAR addition.
Conclusion
PARP-1 clearly contributes in a positive fashion to initia-
tion of gene transcription by inducing local relaxation of
the otherwise condensed chromatin by the attachment of
PAR to the histones H1, H2A and H2B (reviewed in [97]).
The recent demonstration that PARP-1 is closely associ-
ated to the enzyme topoisomerase IIβ (TopoIIβ [98]) fur-
ther stressed the contribution of PARP-1 in the initiation
of gene transcription as TopoIIβ, through its ability to cre-
ate double-strand breaks in DNA, also provides a mean to
activate PARP-1 enzymatic activity as well. Our results
demonstrate that besides its positive action on gene tran-
scription, PARP-1 may as well contribute to suppression
of gene expression by its ability to add PAR to the strong
transcriptional activator Sp1, thereby establishing a dual
regulatory function (activation and repression) for this
protein in gene expression.
Methods
Plasmids and oligonucleotides
The plasmid pCR3 as well as the pCR3 derivative plasmid
that bear mutations in the three most proximal Sp1 bind-
ing sites (F2, F3 and F4; PCR3/F2F3F4m), have both been
previously described [37]. The recombinant plasmids α6–
84 which bear the chloramphenicol acetyltransferase
(CAT) reporter gene fused to a DNA fragment covering the
human α6 gene promoter sequence from positions -84 to
+76 relative to the α6 mRNA start site was constructed as
follow: The pGEM-3Z f(+) AvaI/α6 plasmid that bears the
human α6 gene promoter from position -887 to +76 rela-
tive to the α6 mRNA start site (and generously provided
by Schei Kitazawa, Kobe University School of Medicine,
Kusunoki-Cho, Chuo-Ku, Kobe) was linearized at its
unique KpnI site (5'-end) and treated with the nuclease
Bal31 before being blunted. The 5'-digested α6 promoter
fragments generated were then digested with HindIII (3'-
end at α6 position +76) before being ligated into the
unique SmaI/HindIII sites of the plasmid pGL3 to derive
the pGL3/α6–590 vector. The pGL3/α6–590 construct
was then digested with NheI and blunt-ended with Kle-
now (which then preserved the α6 -590 5'-end), before
being second-digested with XbaI (which preserved the α6
+76 3'-end). The resulting α6 promoter-bearing DNA frag-
ment was then ligated upstream the CAT reporter gene
from the pCATBasic vector (Promega) that has been first
digested with Pst I (5'-end), blunt-ended with Klenow and
second digested with XbaI (3'-end) prior to its dephos-
phorylation with alkalin phosphatase (to yield pCATBa-
sic/α6–590). Removal of the α6 promoter fragment from
the common SphI site (located upstream from α6 pro-
moter position -590 in the multiple cloning site of the
parental plasmid pCATBasic) to the internal restriction
site SacII (at α6 position -84) followed by blunt-ending
with Klenow and ligation with T4 ligase, yielded the plas-
mid  α6–84. The PXGH5 plasmid is a kind gift of Dr.
David D. Moore (Department of Molecular and Cell Biol-
ogy, Baylor College of medicine, Houston, TX, USA). The
double-stranded oligonucleotides bearing the high affin-





GGCGGTGC-3') [101] and NFI (5'-GATCTTATTTT-
GGATTGAAGCCAATATGAG-3') [102] were chemically
synthesized using a Biosearch 8700 apparatus (Millipore,
Bedford, MA, USA).
Cell culture and media
The embryonic fibroblast cell lines derived from both nor-
mal (PARP-1+/+) and PARP-1 knockout mice (PARP-1-/-)
[52] were grown in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), and gentamycin (20 μg/mL). Human skin keratino-
cytes (HSKs) were isolated from a normal adult skin spec-
imen (26 year-old donor) removed during reductive
breast surgery and grown on a feeder layer of irradiated
mouse Swiss 3T3 fibroblasts in complete keratinocyte
medium as described [103]. Cells were maintained at
37°C, under a 5% CO2  controlled atmosphere in a
humidified incubator. When indicated, both PARP-1+/+
cells and HSKs were grown in the presence of either 300
μM hydrogen peroxide (H2O2) for 10 min, and/or 1 μM
PARP-1 inhibitor PJ34 for either 24 h (PARP-1+/+ cells) or
for 4-, 24- and 72 h (HSKs); cells were also re-challenged
(1 h prior to harvesting for PARP-1+/+cells, or every 24 h
for HSKs) before they were harvested for the preparation
of the nuclear extracts.
SDS-PAGE and Western Blot
The protein concentration from the nuclear extracts pre-
pared from PARP-1+/+ and PARP-1-/- cells was determinedBMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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by the Bradford procedure and precisely validated
through Coomassie blue staining on 10% SDS-polyacry-
lamide gels (a typical example can be seen on Figure 3B).
Either 20 μg nuclear proteins was added to 1 volume of
sample buffer (6 M urea, 63 mM Tris (pH6.8), 10% (v/v)
glycerol, 1% SDS, 0,00125% (w/v) bromophenol blue,
300 mM β-mercaptoethanol) and then size-fractionated
on a 10% SDS-polyacrylamide minigel before being trans-
ferred onto a nitrocellulose filter. The blot was then
washed in TS (150 mM NaCl, 10 mM Tris-HCl pH7.4)
and TSM buffers (TS buffer with 5%milk and 0,1% Tween
20) as described previously [58]. The membrane was fur-
ther incubated for 1 h at 22°C with a 1:5000 dilution
(except for the PARP-1 Ab (C-2-10) that has been used at
a 1/10 000 dilution) of the following primary antibodies:
rabbit polyclonal antibodies directed against the tran-
scription factors Sp1 (sc-59; Santa Cruz Biotechnology,
Inc. Santa Cruz, CA), Sp3 (sc-644; Santa Cruz Biotechnol-
ogy), NFI (Santa Cruz Biotechnology, Inc.), c-jun (sc-44x;
Santa Cruz Biotechnology), E2F1 (sc-193; Santa Cruz Bio-
technology), and STAT-1 (G16920; Transduction Labora-
tories, BD Biosciences, Mississauga, CA), polyclonal Abs
directed against a peptide from the C-terminal part of the
PARP-1 automodification domain (422), or against PAR
(LP-9610 or 10-H antibodies), or a mouse monoclonal
antibody (C-2-10) raised against bovine PARP (both the
96-10 and C-2-10 Abs were bought from Dr. Guy Poirier,
Unit of Health and Environment, CHUL Research Center,
Québec, Canada). Membranes were also blotted with a
mouse monoclonal antibody directed against β-actin
(CLT9001, Jackson Immuno Research laboratories inc.;
1:35000 dillution), which has been used for normaliza-
tion purposes. The blot was then washed and incubated
with a 1:1000 dilution of a peroxidase-conjugated goat
anti-rabbit (for the Sp1, Sp3, NFI, PARP-1 (422), p(ADP)r
(LP-9610)) or anti-mouse (for the PARP-1 C-2-10 Ab)
immunoglobulin G (Jackson Immunoresearch Lab.) and
immunoreactive complexes revealed using a Western blot
Detection Kit (Amersham, Baie d'Urfé, Canada). Each
Western blot result shown in this study corresponds to
one out of at least three representative experiments.
Nuclear extracts and electrophoretic mobility shift assay 
(EMSA)
Crude nuclear extracts were prepared as described [104]
from both the PARP-1+/+ and PARP-1-/-cell lines and dia-
lyzed against DNaseI buffer (50 mM KCl, 4 mM MgCl2, 20
mM K3PO4 (pH 7.4), 1 mM β-mercaptoethanol, 20% glyc-
erol). Extracts were kept frozen in small aliquots at -80°C
until use. EMSAs were carried out by incubating 3 ×
104cpm of 5' end-labeled (32P-γATP) double-stranded oli-
gonucleotides bearing the high affinity binding sites for
the transcription factors Sp1, NFI, AP-1, E2F1, and STAT-
1 with either 5- (for the Sp1 probe) or 10 μg (for the NFI,
AP-1, E2F1 and STAT-1 probes) nuclear proteins in the
presence of 25 ng poly(dI-dC). poly(dI-dC) (Pharmacia-
LKD) in buffer D (5 mM HEPES; 10% glycerol; 0,05 mM
EDTA; 0,125 mM PMSF). When indicated, unlabeled dou-
ble-stranded oligonucleotides bearing various DNA target
sequences for known transcription factors (Sp1, NFI) were
added as unlabeled competitors (100- and 500-fold molar
excesses) during the assay. The EMSA experiment with the
Sp1 from the in vitro PARP assay (16 μl from the reaction
mix was used for each lane) was conducted as above
except that poly(dI-dC) was omitted and that DNA-pro-
tein complexes were separated on a 6% native polyacryla-
mide gel. Supershift experiments in EMSA were conducted
by adding antibodies (400 ng) directed against Sp1, Sp3
and NFI to the above reaction mixtures. Incubation pro-
ceeded at room temperature for 5 min upon which time
DNA-protein complexes were separated by gel electro-
phoresis through a 8% (for Sp1, AP-1, E2F1 and STAT-1)
or 10% (for NFI) native polyacrylamide gel run against
Tris-glycine buffer as described [105]. Gels were dried and
autoradiographed at -80°C to reveal the position of the
shifted DNA-protein complexes.
Immunoprecipitation assay
The immunoprecipitation of the Sp1 complexes was per-
formed as follow: approximately 300 μg nuclear extracts
from the PARP-1+/+ and PARP-1-/- cell lines was mixed
with either the anti-Sp1 antibody (2 μg; Santa Cruz) or
normal rabbit IgG (2 μg; Santa Cruz) overnight at 4°C,
either alone, or in the presence of 100 μg/ml ethidium
bromide [22,106], in binding buffer (10 mM Tris-HCl, 20
mM MgCl2, 150 mM NaCl, 1 mM dithiothreitol, 10% (v/
v) glycerol, 1 mM PMSF). Protein-A-Sepharose (Sigma-
Aldrich) was then added to the mixtures containing the
cell extracts and incubated further for 5 h at 4°C. Samples
were centrifuged and the protein A-Sepharose pellet
washed four times in binding buffer before being resus-
pended in SDS sample buffer (6 M urea, 63 mM Tris (pH
6,8), 10% (vol/vol) glycerol, 1% SDS, 0,00125% (wt/vol)
bromophenol blue, 300 mM β-mercaptoethanol). The
immunoprecipitated samples were then used for Western
blot analyses using the Sp1 (sc-59), PARP-1 (C-2-10) and
PAR (LP-9610) antibodies. To immunoprecipitate the
PARP-1 complexes, PARP-1+/+ and PARP-1-/- cells were cul-
tured as described above and then harvested in lysis buffer
(1% (v/v) NP-40, 175 mM KPO4, 150 mM NaCl, 1 mM
dithiothreitol, 0,5 mM PMSF). The cell lysates were incu-
bated for 1 h at 4°C and then cleared by centrifugation at
13,000 rpm for 10 min at 4°C. The anti-PARP-1 polyclo-
nal antibody F-123 (100 μl) attached to protein A-Sepha-
rose was then added to the cell lysates and the reaction
mix incubated for 2 h at 4°C. The beads were pelleted by
centrifugation, washed four times in lysis buffer and
finally resuspended in SDS sample buffer. The immuno-
precipitated samples were then used for Western blotBMC Molecular Biology 2007, 8:96 http://www.biomedcentral.com/1471-2199/8/96
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analyses using the Sp1 (sc-59), Sp3 (sc-644), PARP-1
(422) and PAR (LP-9610) antibodies.
In vitro Poly(ADP-ribosyl)ation assay
Recombinant Sp1 protein (250 ng GST-Sp1-8xHis pro-
tein; kindly provided by Dr. Claude Labrie, Oncology and
Molecular Endocrinology Research Center, CHUL) was
incubated for 5 min at 30°C with 1 U of purified bovine
PARP-1 in a standard assay mixture (152 μl) containing
100 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 10% (v/v) glyc-
erol, 1.5 mM DTT, 10 μg/ml activated DNA (DNaseI
treated) and 200 μM NAD+ [107]. The reaction was termi-
nated by the addition of SDS sample buffer (6 M urea, 63
mM Tris (pH 6,8), 10% (vol/vol) glycerol, 1% SDS,
0,00125% (wt/vol) bromophenol blue, 300 mM β-mer-
captoethanol), and the resulting mixture subjected to
Western blot analysis with the PARP-1 (C-2-10), Sp1 (sc-
59) and PAR (LP-9610) antibodies. When indicated, the
PARP inhibitor PJ34(Alexis Biochemicals, San Diego CA)
was added to the reaction mixture at a final concentration
of 100 mM along with purified PARP-1 15 min prior to
the addition of the recombinant Sp1 protein.
Erasable blot
Samples from the in vitro PARP assay were electro-
phoresed on 10% SDS-PAGE and electrotransfered onto
nitrocellulose membranes at 50 V. The PAR covalently
linked onto the automodified PARP-1 and Sp1 proteins
transferred on the membranes was erased by incubation
with poly(ADP-ribose) glycohydrolase (PARG) according
to a previously described procedure [108]. The blots were
subsequently soaked in TS (150 mM NaCl, 10 mM Tris-
HCl pH7.4) containing 0,1% (v/v) Tween-20 and 5%
non-fat milk (TSM) for 1 hour and then soaked in a solu-
tion of 50 mM KPO4, pH 7,4, 50 mM KCl, 5 mM β-mer-
captoethanol, 10% (v/v) glycerol, 0,1% (v/v) Triton X-100
containing 2,5 U/mL of purified calf thymus PARG [109]
for 2 hours at room temperature. Membranes were
washed four times with 10 mL of renaturation buffer (150
mM NaCl, 10 mM Tris-HCl pH7.4) at 15 min intervals.
The membranes were finally blotted with antibodies
directed against PARP-1 (C-2-10), Sp1 (sc-59) and PAR
(LP-9610).
Transient transfection and CAT assay
PARP-1+/+ and PARP-1-/- cells were grown on tissue culture
plates and transiently transfected 24 h later using the poly-
cationic detergent Lipofectamine (Invitrogen-Gibco, On,
Canada) following the procedure recommended by the
manufacturer. When indicated, the PARP inhibitor PJ-34
(1 μM; Alexis Biochemicals) was added 3 h post-transfec-
tion. Each Lipofectamine-transfected plate received 1 μg
of the PCR-CAT test plasmid and 1 μg pXGH5, which
bears a secreted version of the human growth hormone
gene upstream the mMT-I promoter [110]. Levels of CAT
activity for all transfected cells were determined as
described [111] and normalized to the amount of hGH
secreted into the culture media and assayed using a kit for
quantitative measurement of hGH (Immunocorp, Mon-
tréal, Québec). The value presented for each individual
test plasmid transfected corresponds to the mean of at
least three separate transfections done in triplicate. Stu-
dent's t-test was performed for comparison of the groups.
To be considered significant, each individual value
needed to be at least three times over the background level
caused by the reaction buffer used (usually corresponding
to 0.15% chloramphenicol conversion). Each single value
was expressed as 100 × (% CAT in 4 h)/100 μg protein/ng
hGH. Differences were considered to be statistically signif-
icant at P < 0.05. All data are expressed as mean ± SD.
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